IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

National cancer institute sponsored study of classifications of non-hodgkin's lymphomas. Summary and description of a working formulation for clinical usage

1982 • 3,027 citations

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

1994 • 1,932 citations

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1982 • 1,001 citations

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

1994 • 747 citations

Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support

1993 • 665 citations

CD20: a regulator of cell-cycle progression of B lymphocytes

1994 • 583 citations

Radioimmunotherapy of B-Cell Lymphoma with [¹³¹I]Anti-B1 (Anti-CD20) Antibody

1993 • 557 citations

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas

1995 • 447 citations

A clinical trial of anti-idiotype therapy for B cell malignancy

1985 • 434 citations

Croonian lecture.—On immunity with special reference to cell life

1900 • 427 citations

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.

1996 • 410 citations

Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas

1987 • 360 citations

Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.

1996 • 336 citations

High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma.

1997 • 242 citations

Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.

1992 • 208 citations

Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma.

1994 • 207 citations

A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy

1993 • 185 citations

Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon

1989 • 182 citations

2-Chlorodeoxyadenosine treatment of low-grade lymphomas.

1992 • 172 citations

Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study.

1992 • 164 citations

Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes

1986 • 146 citations

A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma

1996 • 140 citations

Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.

1995 • 113 citations

Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells

1992 • 83 citations

Treatment approaches to the low-grade lymphomas

1994 • 77 citations

2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma.

1994 • 74 citations

Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation

1984 • 62 citations

Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma.

1986 • 56 citations

Phase I Trial of an Anti-CD19 Deglycosylated Ricin A Chain Immunotoxin in Non-Hodgkinʼs Lymphoma

1995 • 41 citations

Fludarabine: A Phase II Trial in Patients with Previously Treated Low-Grade Lymphoma

1996 • 22 citations